ARTICLE | Finance

Adaptive's $195M discovery

Why Adaptive's $195M series F lets the immune sequencer enter target discovery

May 11, 2015 7:00 AM UTC

Armed with one of the biggest venture equity rounds in the history of biotech, immune sequencing company Adaptive Biotechnologies Corp. has decided the time is ripe to dip its toes into therapeutic discovery. The move will be gradual and does not represent a departure from diagnostic development.

According to BioCentury's BCIQ database, last week's $195 million series F round is the seventh-largest private round ever for biotechs, excluding venture debt and royalty deals...